Isoliquiritigenin could improve inflammation and oxidative stress through suppressing the Toll-like receptor 4 (TLR4)/NF-κB/NLRP3 signaling pathway in mice with diabetic kidney disease (Table 1) (Wang et al., 2024). The gene discussed is TLR4; the disease is diabetic kidney disease.